Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Labcorp Companion Diagnostic for BRAF-Mutated Melanoma

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at precisionmedicineonline.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

The FDA has approved Labcorp's companion diagnostic test for detecting BRAF-mutated melanoma, enabling targeted treatment decisions in oncology.

This Wire brief sits within Fusion42's coverage of Diagnostics.

◆ ◆ The Wire takeaway

Labcorp's FDA approval opens a door for you to integrate specific genetic tests into melanoma care, turning diagnostics into a direct sales channel. This approval pressures competitors to accelerate their own companion diagnostic developments or risk losing access to oncologists at leading immuno-oncology practices.

◆ Coverage

1 source · 10 Aug 2026

◆ Related on Wire

◆ Topics

Diagnosticsfda-approvalcompanion-diagnosticbraf-melanomaprecision-medicineoncology